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Antimicrobial resistance (AMR) is a major public health threat that will cause an estimated 10 million 
deaths worldwide by 2050. [1] Because antimicrobial use drives selection and transmission of AMR, 
[2, 3] there is an urgent need to continue to develop, evaluate, and implement effective, evidence-
based antimicrobial stewardship (AMS) interventions that safely reduce antimicrobial use in both 
primary and secondary healthcare. [4, 5] 
AMS interventions can benefit individual patients, but are often viewed as trading potential increased 
short-term individual disbenefit for long-term societal gain, [6] and so some consider them ‘bedside 
rationing’. [7] The need to consider the ethical implications of AMS programmes, and acceptable 
trade-offs, will increase as antimicrobial prescribing is reduced and programmes are investigated 
among patients with an increased chance of benefit from antimicrobials.   
While there is a clear need to ensure that reductions in antimicrobial use are not at the expense of 
patient outcomes, most current research considers these outcomes separately. AMS studies are 
therefore generally powered on only one of these aspects (typically antimicrobial use), and as  a result, 
are frequently underpowered to detect clinically meaningful differences in important clinical 
secondary outcomes, and do not pre-specify whether between-group differences in clinical outcomes 
will be investigated under superiority, non-inferiority, or equivalence hypotheses. 
This article describes the use of co-primary outcomes as a solution to this problem, presents two 
examples of co-primary outcomes in AMS intervention trials, and argues for their routine use in AMS 
intervention evaluations. 
Co-primary outcomes involve the use of two or more primary outcomes, where rejecting both null 
hypotheses is necessary for the intervention to be declared effective. This contrasts with studies that 
have multiple primary outcomes where rejecting the null hypothesis for at least one (i.e. alternative 
primary outcomes) determines effectiveness. The use of co-primary outcomes in AMS intervention 
research encourages researchers to pay close attention to both antimicrobial use and patient-relevant 
measures (e.g. recovery from illness, safety outcomes), ensuring the study is adequately designed to 
simultaneously answer both questions. Thus, any reduction in antibiotic use must be judged in 
conjunction with any negative impact on patient recovery. Additional sample size considerations for 
trials with co-primary outcomes include the assumed correlation between outcomes and the overall 
power of the study. When outcomes are completely independent, the overall power (to detect similar 
effect sizes in both outcomes) is the product of the power for each individual outcome, and only when 
they are perfectly correlated is the overall power unaffected. [8] 
The PACE study (General practitioner use of a C-reactive protein point-of-care test to help target 
antibiotic prescribing in patients with acute exacerbations of chronic obstructive pulmonary disease) 
determined the effectiveness of C-reactive Protein (CRP) point-of-care testing on safely reducing 
antibiotic use in patients presenting in primary care with an acute exacerbation of chronic obstructive 
pulmonary disease (AECOPD). [9] The study used two co-primary outcomes: i.) Antibiotic use for 
AECOPD within the first four-weeks post-randomisation; ii.) COPD health status, as measured by the 
COPD Clinical Questionnaire at two-weeks post-randomisation. These co-primary outcomes were 
investigated for superiority and non-inferiority respectively. The study aimed to recruit 650 
participants in order to achieve between 81% and 90% power to detect a 20% absolute difference in 
antibiotic use, and a COPD health status that is no worse (with a non-inferiority margin of 0.3). 
The BATCH study (Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with 
confirmed or suspected bacterial infection) is investigating the effect of procalcitonin-guided 
management on antibiotic use in children with severe bacterial infection. [10] The co-primary 
outcomes for the study are i.) Number of days of intravenous (IV) antibiotic therapy, and; ii.) Safety 
(comprising unscheduled admissions/re-admissions; re-treatment for same condition within 7 days of 
stopping IV antibiotics; mortality). The study aims to recruit 1942 participants to achieve between 99% 
power to detect a decrease in antibiotic duration and 90% power to test non-inferiority in safety. 
Assuming that the antibiotic use and safety primary outcomes are independent, this will give at least 
89% power for the combined analysis. 
Reducing antimicrobial use is essential to preserving antimicrobial effectiveness, but should not harm 
patients in the process. AMS intervention evaluations must consider the clinical implications of 
changed antimicrobial use, and the use of co-primary outcomes ensures that both use and safety 
outcomes are considered jointly. Researchers in this field are encouraged to consider the use of co-
primary outcomes, and research funders should consider mandating this dual focus when 
commissioning AMS intervention studies. 
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